Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010 Dec;62(4):588-631.
doi: 10.1124/pr.110.003004.

International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB₁ and CB₂

Affiliations
Review

International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB₁ and CB₂

R G Pertwee et al. Pharmacol Rev. 2010 Dec.

Abstract

There are at least two types of cannabinoid receptors (CB(1) and CB(2)). Ligands activating these G protein-coupled receptors (GPCRs) include the phytocannabinoid Δ(9)-tetrahydrocannabinol, numerous synthetic compounds, and endogenous compounds known as endocannabinoids. Cannabinoid receptor antagonists have also been developed. Some of these ligands activate or block one type of cannabinoid receptor more potently than the other type. This review summarizes current data indicating the extent to which cannabinoid receptor ligands undergo orthosteric or allosteric interactions with non-CB(1), non-CB(2) established GPCRs, deorphanized receptors such as GPR55, ligand-gated ion channels, transient receptor potential (TRP) channels, and other ion channels or peroxisome proliferator-activated nuclear receptors. From these data, it is clear that some ligands that interact similarly with CB(1) and/or CB(2) receptors are likely to display significantly different pharmacological profiles. The review also lists some criteria that any novel "CB(3)" cannabinoid receptor or channel should fulfil and concludes that these criteria are not currently met by any non-CB(1), non-CB(2) pharmacological receptor or channel. However, it does identify certain pharmacological _targets that should be investigated further as potential CB(3) receptors or channels. These include TRP vanilloid 1, which possibly functions as an ionotropic cannabinoid receptor under physiological and/or pathological conditions, and some deorphanized GPCRs. Also discussed are 1) the ability of CB(1) receptors to form heteromeric complexes with certain other GPCRs, 2) phylogenetic relationships that exist between CB(1)/CB(2) receptors and other GPCRs, 3) evidence for the existence of several as-yet-uncharacterized non-CB(1), non-CB(2) cannabinoid receptors; and 4) current cannabinoid receptor nomenclature.

PubMed Disclaimer

Figures

Fig. 1.
Fig. 1.
The structures of (−)-Δ9-tetrahydrocannabinol [(−)-Δ9-THC], HU-210, CP55940, R-(+)-WIN55212, anandamide, and 2-AG.
Fig. 2.
Fig. 2.
The structures of the CB1-selective agonists ACEA, arachidonylcyclopropylamide (ACPA), methanandamide, and noladin ether and of the CB2-selective agonists JWH-133, HU-308, JWH-015, and AM1241.
Fig. 3.
Fig. 3.
The structures of the CB1-selective antagonists/inverse agonists, rimonabant, AM251, AM281, LY320135, and taranabant and of the CB2-selective antagonists/inverse agonists SR144528 and AM630.
Fig. 4.
Fig. 4.
The structures of NESS O327 and O-2050.
Fig. 5.
Fig. 5.
The structures of (−)-11-hydroxy-Δ8-tetrahydrocannabinol, ajulemic acid, cannabinol, cannabidiol, abnormal-cannabidiol, O-1602, cannabigerol, virodhamine, and N-arachidonoyl dopamine.
Fig. 6.
Fig. 6.
Neighbor joining tree showing relationships between the human cannabinoid CB1 and CB2 receptors and other human rhodopsin α-group type G protein-coupled receptors. The tree was generated using the multiple sequence alignment program ClustalX, with bootstrapping (1000 bootstrap trials), and viewed using NJ plot. The tree shows receptors that are discussed in section IV.A of this review; the muscarinic acetylcholine receptors M1–M5 are included as an outgroup.
Fig. 7.
Fig. 7.
Neighbor joining tree showing relationships between human GPR55 and other human rhodopsin δ-group type G protein-coupled receptors. The tree was generated using the multiple sequence alignment program ClustalX, with bootstrapping (1000 bootstrap trials), and viewed using NJ plot. The tree shows receptors that are discussed in section IV.B of this review.

Similar articles

Cited by

References

    1. Abadji V, Lin S, Taha G, Griffin G, Stevenson LA, Pertwee RG, Makriyannis A. (1994) (R)-methanandamide: a chiral novel anandamide possessing higher potency and metabolic stability. J Med Chem 37:1889–1893 - PubMed
    1. Adam L, Salois D, Rihakova L, Lapointe S, St-Onge S, Labrecque J, Payza K. (2007) Positive allosteric modulators of CB1 receptors, in 17th Annual Symposium of the Cannabinoids; 2007 Jun 26–Jul 1; St-Sauveur, Canada p. 86 International Cannabinoid Research Society, Burlington, Vermont
    1. Ahluwalia J, Urban L, Bevan S, Nagy I. (2003a) Anandamide regulates neuropeptide release from capsaicin-sensitive primary sensory neurons by activating both the cannabinoid 1 receptor and the vanilloid receptor 1 in vitro. Eur J Neurosci 17:2611–2618 - PubMed
    1. Ahluwalia J, Yaqoob M, Urban L, Bevan S, Nagy I. (2003b) Activation of capsaicin-sensitive primary sensory neurones induces anandamide production and release. J Neurochem 84:585–591 - PubMed
    1. Akiyama TE, Sakai S, Lambert G, Nicol CJ, Matsusue K, Pimprale S, Lee YH, Ricote M, Glass CK, Brewer HB, Jr, et al. (2002) Conditional disruption of the peroxisome proliferator-activated receptor gamma gene in mice results in lowered expression of ABCA1, ABCG1, and apoE in macrophages and reduced cholesterol efflux. Mol Cell Biol 22:2607–2619 - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources

  NODES
INTERN 4
twitter 2